Poolbeg Pharma has released new data from a human challenge trial that shows its treatment has strong potential in dampening inflammation in blood and tissues in influenza and other viral infections.
POLB 001 showed success in reducing multiple markers of systemic and local inflammation compared with placebo, and a significant reduction in p38 MAP kinase-driven cytokines. Cytokines can sweep throughout the body and cause tissue damage and shut down circulation and other essential organs.
POLB 001 is a viral strain agnostic, small molecule immunomodulator being developed to address severe influenza and other acute inflammatory conditions.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
